logo
Scientists raise ‘urgent concerns' over new bat viruses discovered in China

Scientists raise ‘urgent concerns' over new bat viruses discovered in China

Yahoo6 hours ago

Researchers have raised 'urgent concerns' after discovering two new bat viruses in China with the potential to infect humans and cause severe brain inflammation and respiratory disease.
The viruses, along with multiple new bacteria and parasite species, were discovered in bats inhabiting orchards in southwestern China's Yunnan province, according to a study published on Tuesday in the journal PLoS Pathogens.
These viruses are closely related to the deadly Nipah and Hendra pathogens, which cause severe brain inflammation and respiratory disease in humans, according to researchers, including from the Yunnan Institute of Endemic Disease Control and Prevention.
Nipah is a lethal pathogen known to cause severe disease in humans, including acute respiratory distress with a high mortality rate of 35-75 per cent.
The Hendra virus has been responsible for multiple fatal outbreaks in humans and horses.
'These viruses are naturally hosted by fruit bats and are typically transmitted to humans through bat urine or saliva, often via contamination of food sources,' researchers said.
The study raises concerns about the potential for similar new viruses to spread from bats to livestock or humans in the region.
'This finding is particularly significant as Yunnan province is a recognised hotspot for bat diversity,' it notes.
Due to their unique immune systems, bats are a natural reservoir for a wide range of microorganisms, including notable pathogens transmitted to humans.
While the exact origins of the Covid-19 pandemic remain unclear, numerous studies suggest horseshoe bats as one of the most likely host candidates from which the novel coronavirus jumped to humans.
However, the complete array of viruses, fungi, bacteria and parasites that infect bats remains unknown as most previous studies have focused on faeces from the flying mammal alone without inspecting the organs.
The latest study peered inside the kidneys of 142 bats from 10 species, which were collected over four years across five areas of Yunnan.
Genome sequencing of the samples revealed 22 viruses, of which 20 are new to science.
Two of these were henipaviruses, the same genus as Nipah and Hendra, which have had high fatality rates in humans in previous epidemic outbreaks.
Since these viruses can potentially spread through urine, scientists raise concerns about the risk of these pathogens jumping to humans or livestock via contaminated fruit from the orchards.
The findings underscore the need for a multi-organ screening approach to understand the microbial diversity harboured by bats.
Scientists call for 'comprehensive, full-spectrum microbial analyses of previously understudied organs to better assess spillover risks from bat populations'.
"By analysing the infectome of bat kidneys collected near village orchards and caves in Yunnan, we uncovered not only the diverse microbes bats carry, but also the first full-length genomes of novel bat-borne henipaviruses closely related to Hendra and Nipah viruses identified in China,' they say.
Researchers have also expressed 'urgent concerns about the potential for these viruses to spill over into humans or livestock'.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Capital Push Powering India's Defence-Tech Leap
The Capital Push Powering India's Defence-Tech Leap

Entrepreneur

time23 minutes ago

  • Entrepreneur

The Capital Push Powering India's Defence-Tech Leap

India's defence-tech landscape is undergoing a revolution, driven by a mix of policy liberalisation, heightened geopolitical urgency, and an emerging breed of deeptech startups. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. India's defence-tech landscape is undergoing a revolution, driven by a mix of policy liberalisation, heightened geopolitical urgency, and an emerging breed of deeptech startups. Since 2020, the Indian government has actively encouraged domestic innovation in critical technologies through initiatives such as the Defence Acquisition Procedure (DAP) 2020 and the iDEX (Innovations for Defence Excellence) framework. These are aimed at reducing India's reliance on imports, which still account for around 36 per cent of India's total defence procurement, according to SIPRI data as of 2023. Venture capital firms like Speciale Invest have seized the moment. "We saw a generational opportunity," says Vishesh Rajaram, pointing to a strategic shift where private capital is beginning to back first-principles engineering in a sector historically dominated by government labs and public sector undertakings. Startups such as GalaxEye Space. QNu Labs, Astrogate Labs, and Kawa Space are technologies that previously lacked domestic equivalents. Startups like these are not only aligning with India's Indigenisation List (MoD, 2023) but are also exploring dual-use commercial applications across telecommunications, logistics, and energy. "At Speciale Invest, we invested early on India's defence-tech sector because we saw a generational opportunity, one where innovation is not just encouraged, but imperative. The convergence of deeptech capabilities in AI, autonomy, space, and advanced manufacturing, combined with a supportive policy environment, convinced us that India was ready to build mission-critical technologies from first principles," said Rajaram. Navigating defence's characteristically long development and procurement cycles, which often stretch more than half a decade, remains a hurdle. Yet, according to the Ministry of Defence's iDEX progress report, over 150 contracts have been signed with startups since its inception, signalling an unprecedented openness to private-sector innovation. Rajaram said, "Navigating long sales cycles and regulatory complexity requires patience, strategic alignment with defence end-users, and partnering with founders who understand the unique duality of this sector, where innovation must meet both operational reliability and sovereign requirements." Looking ahead, India's ambitions are global. The Ministry of Defence has set a target to increase defence exports to INR 35,000 crore (~USD 4.2 billion) by 2025, up from INR 15,920 crore in 2023. As Rajaram observes, India is poised to become a net exporter of cutting-edge technologies, particularly in Positioning, Navigation, and Timing (PNT), ISR (Intelligence, Surveillance, Reconnaissance) systems, and drone warfare, areas that are increasingly vital in both conventional and hybrid conflict scenarios. "The current geopolitical climate has accelerated demand for indigenous solutions, and we believe Indian startups will not only serve the domestic market but also become key players in allied export corridors," noted Rajaram. The evolving geopolitical landscape, from border tensions with China to maritime rivalries in the Indo-Pacific, has only intensified the need for self-reliance and export-oriented innovation.

Epilepsy Medications Drive Adverse Pregnancy Outcomes
Epilepsy Medications Drive Adverse Pregnancy Outcomes

Medscape

time36 minutes ago

  • Medscape

Epilepsy Medications Drive Adverse Pregnancy Outcomes

TOPLINE: Maternal epilepsy was associated with increased odds of adverse perinatal outcomes, but most associations were driven by prenatal exposure to antiseizure medications (ASMs) rather than epilepsy itself. METHODOLOGY: Researchers conducted a retrospective population-based cohort study using national health data from Scotland between 2009 and 2021. This study included 629,200 pregnancies (2022 in women with epilepsy and 627,178 in women without epilepsy). International Classification of Diseases, Tenth Revision codes were used to identify maternal epilepsy from pregnancy records or hospital admissions within 2 years prior to the estimated conception through pregnancy. The analysis included exposure to ASMs, defined as any ASM dispensed between 30 days before the estimated conception and the end of pregnancy, with 4406 pregnancies exposed to ASMs and 624,794 unexposed. The primary outcome was the association between maternal epilepsy and adverse perinatal outcomes; secondary outcomes included effect estimates for exposure to specific ASM monotherapies (valproate, carbamazepine, lamotrigine, levetiracetam, or topiramate) vs no exposure. TAKEAWAY: Compared with women without epilepsy, those with epilepsy showed increased odds of induced labour (adjusted odds ratio [aOR], 1.17; 95% CI, 1.02-1.34), after adjusting for prenatal exposure to ASMs. Prenatal exposure to ASMs was associated with increased odds of preterm birth (aOR, 1.47; 95% CI, 1.25-1.74), induced labour (aOR, 1.38; 95% CI, 1.25-1.52), and NICU admission (aOR, 1.54; 95% CI, 1.33-1.78). Valproate monotherapy showed the strongest association with congenital conditions (aOR, 3.91; 95% CI, 2.36-6.49), followed by carbamazepine monotherapy (aOR, 1.90; 95% CI, 1.16-3.10). IN PRACTICE: "Maternal epilepsy is associated with many adverse perinatal outcomes, but most are driven by prenatal ASM exposure. We postulate that joint comprehensive care between obstetricians and epileptologists or other specialists who prescribe ASMs could improve perinatal outcomes," the authors of the study wrote. SOURCE: This study was led by Paolo Pieirino Mazzone, Muir Maxwell Epilepsy Centre, University of Edinburgh, Edinburgh, Scotland, and was published online on June 16, 2025, in Epilepsia. LIMITATIONS: This study was limited by its inability to account for epilepsy characteristics such as aetiology, type/syndrome, or seizure frequency/severity. This study could not determine whether individuals in the group of women with epilepsy without prenatal exposure to ASMs were misclassified because some might have had resolved epilepsy or never had epilepsy. ASM treatment duration, trimester of dispensation, and reasons for ASM use aside from epilepsy were not investigated. DISCLOSURES: This study did not receive any external funding. One author reported receiving consultant, lecture, and/or conference-attendance fees from various sources, and another author reported receiving external fund support unrelated to this study. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Thailand takes further step to tighten control on sales of cannabis
Thailand takes further step to tighten control on sales of cannabis

Washington Post

time40 minutes ago

  • Washington Post

Thailand takes further step to tighten control on sales of cannabis

BANGKOK — Thai authorities said Wednesday the country is taking further steps to tighten control of cannabis sales after the health minister signed an order banning sales of the plant to those without prescriptions. Thailand became the first country in Asia to decriminalize cannabis in 2022, in a move that boosted Thailand's tourism and farming, and spawned thousands of shops . But the country has faced public backlash over allegations that under-regulation has made the drug available to children and caused addiction. Health Minister Somsak Thepsutin on Monday signed an order that bans shops from selling cannabis to customers without a prescription. It also seeks to reclassify cannabis buds as a controlled herb. Phanurat Lukboon, secretary-general of the Office of the Narcotics Control Board, said Wednesday that his agency is ready to study and implement the change in regulations. The order is set to be effective as soon as it is published in the Royal Gazette, although it is unclear when this will happen. The ruling Pheu Thai Party previously promised to criminalize the drug again, but faced strong resistance from its former partner in the coalition government, the Bhumjaithai Party, which supported the decriminalization. Bhumjaithai quit the coalition last week over a leaked phone call between Prime Minister Paetongtarn Shinawatra and a former Cambodian leader Hun Sen. Somsak told reporters on Tuesday that he would like to relist cannabis as a narcotic in the future. The move came after officials last month revealed that cannabis smuggling cases involving tourists had soared in recent months. Phanurat said that a study done by his agency last year found the number of people addicted to cannabis had spiked significantly after it was decriminalized. Government spokesperson Jirayu Houngsab said in a statement Tuesday that the government ordered the Health Ministry to tighten control on sales of cannabis because 'many shops opened to sell cannabis both for recreational and medical purposes, allowing easy access for children and general people, which contradicts the government's purpose to crack down on drugs.' A group of cannabis advocates said Wednesday that the change in regulations was politically motivated. The group said they will rally at the Health Ministry next month to oppose the change and the attempt to make it a criminal offense again to consume or sell cannabis.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store